Novo signs $550M pact with RNA startup Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 28 August, 2025

Expert Mammalian Protein CDMO Services—Scalable, High-Quality Biomanufacturing from Avid Bioservices! sponsored by AVID BIOSERVICES

news In Focus Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite loss Novo's first obesity deal under new CEO is a $550M pact with RNA startup Replicate Updated: Trump administration pushes out CDC director, setting disease agency into turmoil as staff follow Protein degrader startup Plexium raises $60M, loses Amgen pact Lilly pauses Mounjaro orders in the UK just before raising its price

Sep 04 11:00am ET Not just a tool: How AI agents become trial teammates sponsored by Medable Sep 09 11:30pm ET How ctDNA can assist in critical nonoperative management decisions sponsored by Haystack MRD Sep 23 11:00am ET Data you can trust: Setting the bar for ML/LLM-extracted real-world data sponsored by Flatiron Sep 25 11:00am ET Leveraging acoustic focusing for fast and precise high-parameter flow cytometry panels sponsored by Thermo Fisher Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Join us.

endpoints pharma Exelixis to close Pennsylvania site, lay off 130 staffers Indivior to reduce headcount, real estate in first stage of broader reorg FDA approves updated Covid vaccines, including mRNA shots from Pfizer, Moderna FDA talks limitations, potential for cancer registries

in case you missed it 1. Amylyx's old ALS drug fails in another neuro disease, focus turns to GLP-1 2. New research foundation commits $500M to funding 'long bets' in science 3. Wugen collects $115M as it runs pivotal allogeneic CAR-T trial 4. News Briefing Verzenio's survival benefit in early breast cancer; Another RemeGen Phase 3 win 5. Antiva to tweak dosing of HPV drug, seek funding for new trial following mixed early data